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Summary: In diabetic patients, hyperglycaemia results in the non-enzymatic glycation of apolipoprotein A-I,
the major protein of human high density lipoproteins.
The effect of the non-enzymatic glycation on the association of apolipoprotein A-I with high density lipoprotein
in vivo has been studied in the rat.
The distribution volume obtained after injection of glycated apolipoprotein A-I was 2- to 3-fold higher in
kidneys and approximately 30% lower in adrenals and ovaries than that obtained with apolipoprotein A-I.
Analysis by gel chromatography of serum from donor rats shows that glycation diminishes the interaction
between apolipoprotein A-I and high density lipoprotein.
The findings in this study suggest that non-enzymatic glycation of apolipoprotein A-I may contribute to the
development of atherosclerosis in patients with diabetes mellitus.
Introduction ,
 u .In this report we document an abnormal association
Excessive non-enzymatic glycation of protein has been of glycated apolipoprotein A-I with high density li-
implicated in the development of several complica- poprotein in vivo in the rat.
tions of diabetes mellitus, including atherosclerotic
vascular disease (1).
Lipoprotein abnormalities are related to the devel- Materials and Methods
opment of atherosclerosis and, therefore, non-enzy- Isolation of high densi ty l ipoprotein, apolipoprotein
matic glycation of the protein moiety of lipoproteins A'1 and glycated apolipoprotein A-I
(apolipoproteins) has been the subject of intensive Human high density lipoprotein (d = 1.063-1.21 kg/1) was
Study. isolated by sequential ultracentrifugation (5). Apolipoprotein
A-I was purified from high density lipoprotein using well es-
Increased non-enzymatic glycation of all major classes tablished procedures (6). Glycated apolipoprotein A-I was pur-
r t. A · i_ ι j A A j - x i ified from the plasma of diabetic patients as previously de-
of apolipoproteins has been demonstrated in the
 scrjbed (4)
plasma of diabetic patients (2, 3).
Alterations of the self-association and lipid-binding Binding in vivo of glycated [1 2 5I]apolipoprotein A-I
properties of apolipoprotein A-I, resulting from its and [1 2 5I]apolipoprotein A-I to organs
non-enzymatic glycation, have been reported in vitro Glycated apolipoprotein A-I (1-2 glucose molecules per apo-
(4), suggesting that this modification in the apolipo- lipoprotein molecule) and apolipoprotein A-I were radioiodi-
* · A T rr ^u + * ι i. · fj· u nated with125! by the chloramine T method (7). For experiments
protein A-I may affect the structural cohesion of high
 involving reassociation of apolipoprotein A-I with high density
density lipoprotein (HDL) particles. lipoprotein in vivo, each labelled apolipoprotein was injected
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via the femoral vein into adult female rats. Two hours later,
the animals were exsanguinated. Serum was immediately sep-
arated and reinjected into acceptor rats for tissue binding stud-
ies. The acceptor rats were exsanguinated via the abdominal
aorta 5 — 7 min after injection. The liver, kidneys, adrenals,
ovaries, spleen, abdominal muscle, heart, lungs and stomach
were removed (normally within 10 min of the injection).
The organs were cleaned, weighed and counted for 125I. The
results were expressed in terms of specific tissue distribution
volumes (DV):
DV (μΐ/g tissue) = counts/min per g organ
counts/mm per μΐ of serum (8)
The non-specific association of radioactivity with the organs,
due to the presence of residual serum after removal of organs,
was estimated by measurement of organ distribution volumes
of albumin in a group of control rats.
Study of associa t ion of 1 2 5 I - label led apo l ipopro te ins
wi th high dens i ty l ipopro te in
The association of glycated apolipoprotein A-I or apolipopro-
tein A-I with high density lipoprotein in vivo was determined
by gel filtration chromatography. The serum obtained two
hours after injection of either glycated [125]apolipoprotein A-I
or [125I]apolipoprotein A-I in a donor animal was applied to a
column (0.9 χ 50 cm) of Sephadex G-150, and eluted with 0.05
mol/1 barbital buffer, pH 8.6. Fractions of 0.5 ml were collected
for measurement of radioactivity.
Sta t is t ica l ana lys is
Differences between means were tested with Student's t test.
Results
The specific tissue distribution volumes obtained after
injection of radioiodinated glycated apolipoprotein Α-
Ι or apolipoprotein A-I are shown in figure 1.
Only four tissues (liver, kidneys, adrenals and ovaries)
were specifically labelled and little or no binding was
detected in the remaining organs.
The adrenals and ovaries were the predominant or-
gans of glycated apolipoprotein A-I and apolipopro-
tein A-I binding. However, the binding of glycated
apolipoprotein A-I was significantly less (p < 0.01)
than the binding of apolipoprotein A-I in these or-
gans.
There was no difference between the distribution vol-
umes of both apolipoproteins in liver.
Of particular interest, the distribution volume deter-
mined with glycated apolipoprotein A-I in the kidneys
was 2- to 3-fold higher than the determined with
apolipoprotein A-I. Previous studies (8, 9) have pro-
posed that the uptake of apolipoprotein A-I by kid-
neys may involve free, rather than high density lipo-
protein-bound apolipoprotein A-I.
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Fig.l. In vivo binding of glycated apolipoprotein A-I (·) and
apolipoprotein A-I (o) to organs in the rats. The tissue
distribution volumes were determined after injection of
the radioiodinated apolipoproteins as described under
Materials and Methods. The results expressed in μΐ/g
of tissue are corrected for the tissue distribution volume
of radioiodinated albumin, considered as representative
of the non-specific association. Each value is the mean
± SEM for 10 animals (**, p < 0.001; *, p < 0.01; NS,
not significant).
Gel filtration of serum obtained from a donor rat
injected with either glycated [125I]apolipoprotein A-I
or [125I]apolipoprotein A-I for reassociation with high
density lipoprotein in vivo shows that virtually all of
the apolipoprotein A-I was associated with high den-
sity lipoprotein; and very little free apolipoprotein Α-
Ι was detected. However, when glycated apolipopro-
tein A-I was reassociated with high density lipopro-
tein, only 70% of radioactivity was associated with
this lipoprotein while the rest remained as free apo-
lipoprotein A-I (fig. 2).
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Fig. 2. Sephadex G-150 gel filtration chromatography of se-
rum obtained 2 h after injection of glycated
[125I]apolipoprotein A-I (·) or [125I]apolipoprotein A-I
(o) into a donor rat. The arrow denotes the elution
volumes of HDL determined in independent calibration
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Discussion
This study shows that glycated apolipoprotein A-I
from diabetic patients behaves differently from the
non-glycated form when injected into rats. The high
uptake of apolipoprotein A-I by adrenals and ovaries
is consistent with previous reports that high density
lipoproteins are the main suppliers of cholesterol for
steroidogenic tissues in the rat (10, 11).
The smaller uptake of glycated apolipoprotein A-I
compared with apolipoprotein A-I in these organs
may reflect the diminished association of glycated
apolipoprotein A-I with high density lipoprotein; our
results agree with those of other authors, who estab-
lished that adrenals and ovaries bind high density
lipoprotein-bound apolipoprotein A-I (8). In contrast,
the preferential uptake of glycated apolipoprotein Α-
Ι by kidneys cannot be explained by uptake of intact
high density lipoprotein particles, but may rather be
attributed to glomerular filtration and tubular reab-
sorption of apolipoprotein A-I that is not associated
with high density lipoprotein (9). This is consistent
with the large amount of free glycated apolipoprotein
A-I detected chromatographically in plasma of donor
rats injected with this apolipoprotein, and it suggests
that free and lipoprotein-bound apolipoproteins may
have different catabolic sites. It was not the purpose
of this study to establish the nature of this binding.
The most reasonable explanation is that in these tis-
sues the high density lipoprotein binding is mediated
by apolipoprotein A-I (12).
The mechanism by which the non-enzymatic glycation
may alter the association of apolipoprotein A-I with
high density lipoprotein is not clear; it is possible,
however, that the presence of covalently-linked glu-
cose molecules on lysine residues in an amphipathic
domain of apolipoprotein A-I could alter the lipid-
protein interaction.
Thus, this abnormality in glycated apolipoprotein Α-
Ι might contribute to the development of atheroscle-
rosis in patients with diabetes mellitus.
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